What's Happening?
A UK-led study, known as the TARTAN-HF trial, has discovered that approximately 24.9% of patients with diabetes and risk factors for heart failure (HF) have undiagnosed HF. Conducted by the University of Glasgow and funded by AstraZeneca, Roche Diagnostics,
and Us2.ai, the study involved 700 subjects at two NHS hospitals in Glasgow. The research introduced a GP-led care pathway that includes an initial consultation, a biomarker blood test, and a cardiac ultrasound. This approach aims to identify HF earlier, allowing for timely treatment that could improve patient outcomes. The findings were presented at the American College of Cardiology congress.
Why It's Important?
The study underscores the significant prevalence of undiagnosed heart failure among diabetics, which can lead to poor long-term health outcomes if not addressed. Early detection and treatment are crucial in managing HF, potentially slowing disease progression and improving quality of life. The research supports NHS England's and NHS Scotland's plans to enhance cardiovascular disease management. This could lead to more efficient use of healthcare resources and better patient care, particularly in primary care settings where early intervention can be most effective.
What's Next?
Researchers are conducting further analyses to understand the cost implications of early HF detection in diabetes patients. The study's findings may influence healthcare policies and practices, encouraging the adoption of similar care pathways across the NHS. This could lead to broader implementation of early screening and treatment strategies, potentially reducing the burden of heart failure on healthcare systems and improving patient outcomes.
